Literature DB >> 15970000

Hormonal manipulations in the luteal phase to coordinate subsequent antral follicle growth during ovarian stimulation.

Renato Fanchin1, Daniel H Méndez Lozano, Luca M Schonäuer, João Sabino Cunha-Filho, René Frydman.   

Abstract

During the early follicular phase in the menstrual cycle, antral follicle sizes are often markedly heterogeneous. These follicular size discrepancies may, at least in part, result from the early exposure of FSH-sensitive follicles to gradient FSH concentrations during the preceding luteal phase. In addition, they potentially affect the results of ovarian stimulation. Indeed, pre-existing follicle size discrepancies may encumber coordinated follicular growth during ovarian stimulation, thereby reducing the number of follicles that reach maturation at once. To investigate this issue, three clinical studies were conducted to test the hypothesis that luteal FSH suppression could coordinate follicular growth. First, luteal FSH concentrations were artificially lowered by administering physiological oestradiol doses and measured follicular characteristics on the subsequent day 3. Second, it was verified whether luteal oestradiol administration could promote the coordination of follicular growth during ovarian stimulation and improve its results. Third, the effects of premenstrual gonadotrophin-releasing hormone (GnRH) antagonist administration on follicular characteristics were assessed during the early follicular phase. The results showed that luteal FSH suppression by either oestradiol or GnRH antagonist administration reduces the size and improves the homogeneity of early antral follicles during the early follicular phase, an effect that persists during ovarian stimulation. Coordination of follicular development may optimize ovarian response to short GnRH agonist and antagonist protocols, and constitutes an attractive approach to improving their outcome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15970000     DOI: 10.1016/s1472-6483(10)61115-7

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  7 in total

1.  Individualised controlled ovarian stimulation (iCOS): maximising success rates for assisted reproductive technology patients.

Authors:  Ernesto Bosch; Diego Ezcurra
Journal:  Reprod Biol Endocrinol       Date:  2011-06-21       Impact factor: 5.211

2.  GnRH antagonist multiple dose protocol with oral contraceptive pill pretreatment in poor responders undergoing IVF/ICSI.

Authors:  Chung-Hoon Kim; Rae-Mi You; Hyuk-Jae Kang; Jun-Woo Ahn; Ilkyung Jeon; Ji-Won Lee; Sung-Hoon Kim; Hee-Dong Chae; Byung-Moon Kang
Journal:  Clin Exp Reprod Med       Date:  2011-12-31

3.  Tadalafil for Endometrial Growth in Clomiphene Citrate stimulated cycles in an IUI programma: A pilot study.

Authors:  D H Mendez Lozano; M V Lenero; R L Gonzalez; J B Scheffer; M T Gonzalez; Y Barron; R Frydman
Journal:  Facts Views Vis Obgyn       Date:  2015-12-28

4.  Pregnancy outcome in delayed start antagonist versus microdose flare GnRH agonist protocol in poor responders undergoing IVF/ICSI: An RCT.

Authors:  Robab Davar; Nosrat Neghab; Elham Naghshineh
Journal:  Int J Reprod Biomed       Date:  2018-04

5.  Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis.

Authors:  Sally Kadoura; Marwan Alhalabi; Abdul Hakim Nattouf
Journal:  Sci Rep       Date:  2022-03-15       Impact factor: 4.379

6.  Comparison of gonadotropin-releasing hormone agonist with GnRH antagonist in polycystic ovary syndrome patients undergoing in vitro fertilization cycle: Retrospective analysis from a tertiary center and review of literature.

Authors:  Neeta Singh; Moumita Naha; Neena Malhotra; Kusum Lata; P Vanamail; Abnish Tiwari
Journal:  J Hum Reprod Sci       Date:  2014-01

7.  Effect of acupuncture on women with poor ovarian response: a study protocol for a multicenter randomized controlled trial.

Authors:  Huanfang Xu; Chensi Zheng; Liyun He; Tongsheng Su; Huidan Wang; Yu Li; Cui Zhao; Cuilian Zhang; Yang Bai; Guoqing Tong; Li Chen; Fang Zhao; Huisheng Yang; Mingzhao Hao; Yaqian Yin; Li Yang; Yigong Fang; Baoyan Liu
Journal:  Trials       Date:  2020-09-10       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.